采用放射免疫分析法测定去羟肌苷。
Didanosine measurement by radioimmunoassay.
作者信息
DeRemer M, D'Ambrosio R, Morse G D
机构信息
Department of Pharmacy Practice, State University of New York at Buffalo, USA.
出版信息
Antimicrob Agents Chemother. 1996 Jun;40(6):1331-4. doi: 10.1128/AAC.40.6.1331.
Abstract
Didanosine is commonly prescribed as monotherapy or as part of a combination regimen for patients with human immunodeficiency virus infection. The use of lower doses, either as part of a combination regimen or as a result of dose reduction secondary to clinical intolerance, requires that a sensitive assay method be available for either traditional or population-based pharmacokinetic evaluations. We evaluated a radioimmunoassay technique with a standard curve range of 0 to 100 ng/ml in human plasma, urine, and cerebrospinal fluid and assessed its accuracy and precision for use in pharmacokinetic studies.
摘要
去羟肌苷通常被开为单一疗法，或作为人类免疫缺陷病毒感染患者联合治疗方案的一部分。使用较低剂量，无论是作为联合治疗方案的一部分，还是由于临床不耐受导致剂量减少，都需要有敏感的检测方法用于传统的或基于群体的药代动力学评估。我们评估了一种放射免疫测定技术，其在人血浆、尿液和脑脊液中的标准曲线范围为0至100 ng/ml，并评估了其在药代动力学研究中的准确性和精密度。
相似文献
1
Didanosine measurement by radioimmunoassay.采用放射免疫分析法测定去羟肌苷。
Antimicrob Agents Chemother. 1996 Jun;40(6):1331-4. doi: 10.1128/AAC.40.6.1331.
2
Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients.大剂量口服更昔洛韦对人类免疫缺陷病毒（HIV）阳性患者中去羟肌苷处置的影响。
J Clin Pharmacol. 1998 Nov;38(11):1057-62. doi: 10.1177/009127009803801111.
3
Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients.人免疫缺陷病毒感染门诊患者中去羟肌苷暴露量与替代标志物反应之间的关系。
Antimicrob Agents Chemother. 1998 Apr;42(4):821-6. doi: 10.1128/AAC.42.4.821.
4
Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.去羟肌苷降低了人类免疫缺陷病毒感染患者中阿替维啶的吸收。
Antimicrob Agents Chemother. 1996 Mar;40(3):767-71. doi: 10.1128/AAC.40.3.767.
5
Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection.去羟肌苷在人类免疫缺陷病毒感染患者中的群体药代动力学。
J Infect Dis. 1996 Jan;173(1):273. doi: 10.1093/infdis/173.1.273.
6
A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.齐多夫定与利巴韦林联合治疗HIV-1疾病患者的安全性、药代动力学及抗病毒活性的I期研究。艾滋病临床试验组231方案团队。
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):235-46. doi: 10.1097/00042560-199611010-00005.
7
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.司他夫定与去羟肌苷联合奈非那韦在暴露于人类免疫缺陷病毒的新生儿中的药代动力学。
Antimicrob Agents Chemother. 2001 Dec;45(12):3585-90. doi: 10.1128/AAC.45.12.3585-3590.2001.
8
Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog.[14C]去羟肌苷在比格犬体内的吸收、分布及代谢
Drug Metab Dispos. 1993 May-Jun;21(3):447-53.
9
Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.去羟肌苷。关于其在治疗HIV疾病中的抗病毒活性、药代动力学特性及治疗效果的最新情况。
Drugs. 1996 Dec;52(6):928-62. doi: 10.2165/00003495-199652060-00014.
10
A radioimmunoassay for the new antiviral agent 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.新型抗病毒药物1-β-D-阿拉伯呋喃糖基-E-5-(2-溴乙烯基)尿嘧啶的放射免疫测定法。
Ther Drug Monit. 1992 Dec;14(6):499-508. doi: 10.1097/00007691-199212000-00011.
引用本文的文献
1
Antiretroviral bioanalysis methods of tissues and body biofluids.组织和生物体液的抗逆转录病毒生物分析方法。
Bioanalysis. 2013 Feb;5(3):351-68. doi: 10.4155/bio.12.319.
2
Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients.硫酸茚地那韦和去羟肌苷在 HIV 感染患者中的多次剂量药代动力学。
Clin Drug Investig. 2003;23(5):323-8. doi: 10.2165/00044011-200323050-00002.
3
Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine.接受双脱氧肌苷治疗的人类免疫缺陷病毒感染患者中双脱氧三磷酸腺苷水平的测定。
Antimicrob Agents Chemother. 2004 Feb;48(2):589-95. doi: 10.1128/AAC.48.2.589-595.2004.
4
Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients.人免疫缺陷病毒感染门诊患者中去羟肌苷暴露量与替代标志物反应之间的关系。
Antimicrob Agents Chemother. 1998 Apr;42(4):821-6. doi: 10.1128/AAC.42.4.821.
5
Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.甲磺酸地拉韦啶与去羟肌苷在人类免疫缺陷病毒感染患者中的单剂量药代动力学
Antimicrob Agents Chemother. 1997 Jan;41(1):169-74. doi: 10.1128/AAC.41.1.169.
本文引用的文献
1
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.齐多夫定与去羟肌苷联合治疗与齐多夫定单药治疗在HIV-1感染中的比较。
Ann Intern Med. 1993 Oct 15;119(8):786-93. doi: 10.7326/0003-4819-119-8-199310150-00003.
2
Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine.
J Infect Dis. 1994 Jun;169(6):1250-5. doi: 10.1093/infdis/169.6.1250.
3
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.齐多夫定与去羟肌苷单独及联合应用于获得性免疫缺陷综合征患者的药代动力学。
Br J Clin Pharmacol. 1994 May;37(5):421-6. doi: 10.1111/j.1365-2125.1994.tb05708.x.
4
Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection.
J Pediatr. 1994 Jul;125(1):142-6. doi: 10.1016/s0022-3476(94)70141-5.
5
A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.一项针对有症状的人类免疫缺陷病毒感染患者进行齐多夫定与去羟肌苷交替或联合治疗的随机试点研究。
J Infect Dis. 1994 Jan;169(1):9-17. doi: 10.1093/infdis/169.1.9.
6
Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.对获得性免疫缺陷综合征或艾滋病相关综合征患者每日一次给予2',3'-双脱氧肌苷（ddI）。一项I期试验的结果。
N Engl J Med. 1990 May 10;322(19):1340-5. doi: 10.1056/NEJM199005103221902.
7
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.2',3'-双脱氧肌苷（ddI）用于获得性免疫缺陷综合征或艾滋病相关综合征患者。一项I期试验。
N Engl J Med. 1990 May 10;322(19):1333-40. doi: 10.1056/NEJM199005103221901.
8
Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography.采用高效液相色谱法对人血浆和尿液中的去羟肌苷进行定量分析。
J Chromatogr. 1990 Nov 30;533:282-90. doi: 10.1016/s0378-4347(00)82215-x.
9
Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.2',3'-双脱氧腺苷和2',3'-双脱氧肌苷在严重人类免疫缺陷病毒感染患者中的药代动力学。
Clin Pharmacol Ther. 1990 May;47(5):647-54. doi: 10.1038/clpt.1990.86.
10
Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.去羟肌苷在获得性免疫缺陷综合征或与获得性免疫缺陷综合征相关综合征患者中的药代动力学。
Clin Pharmacol Ther. 1991 May;49(5):523-35. doi: 10.1038/clpt.1991.63.
Zotero 插件